Patents by Inventor Craig A. McKelvey

Craig A. McKelvey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8486983
    Abstract: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: July 16, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Agam R. Sheth, Bhagwant Rege, Soumojeet Ghosh, Laman L. Alani, Maria T. Cruanes, Craig A. McKelvey
  • Patent number: 8030359
    Abstract: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: October 4, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sarah Geers, Michael Lowinger, Craig A. McKelvey, Robert F. Meyer, Dina Zhang
  • Publication number: 20100227903
    Abstract: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
    Type: Application
    Filed: February 9, 2007
    Publication date: September 9, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Sarah Geers, Michael Lowinger, Craig A. McKelvey, Robert F. Meyer, Dina Zhang
  • Publication number: 20100081642
    Abstract: The present invention relates to pharmaceutical compositions that stabilize and improve the bioavailability of 3-[(1S)- 1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile. In particular, the present invention relates to pharmaceutical compositions that include 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3 -(5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile and at least one pharmaceutical acceptable excipient, such as a mono-, di- or triglyceride.
    Type: Application
    Filed: September 14, 2009
    Publication date: April 1, 2010
    Inventors: Eleni Dokou, Craig A. McKelvey, Kevin R. McKenney, Andrey Peresypkin, Karen C. Thompson, W. Peter Wuelfing
  • Publication number: 20090186926
    Abstract: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 23, 2009
    Inventors: Agam R. Sheth, Bhagwant Rege, Soumojeet Ghosh, Laman L. Alani, Maria T. Cruanes, Craig A. Mckelvey